Wegovy and Mounjaro are two prescription medicines used for weight management in adults living with overweight or obesity. While both help people lose weight, they are not the same. They differ in their ingredients, how they work in the body, dosing schedules, and expected results. Understanding these differences is important for making an informed choice with a healthcare professional in the UK.
Wegovy contains semaglutide, a synthetic version of the naturally occurring hormone GLP-1. GLP-1 signals the brain when the stomach is full, helping to reduce appetite and food intake gradually.
Mounjaro contains tirzepatide, which targets two hormones: GLP-1 and GIP. While GLP-1 reduces hunger, GIP helps the body manage blood sugar more effectively. This dual effect can be useful for people who have, or are at risk of, type 2 diabetes.
Wegovy injection works by gradually reducing appetite. It is administered as a weekly injection under the skin, starting at a low dose that is slowly increased to a maintenance level. Early effects include feeling full sooner and experiencing fewer cravings. Over several months, this leads to a natural reduction in calorie intake and steady, sustainable weight loss. Clinical studies show that Wegovy, when combined with a healthy diet and lifestyle, can help people achieve meaningful weight loss.
Mounjaro injection works on both GLP-1 and GIP hormones, which makes it different from Wegovy. In addition to reducing appetite, it can improve how the body regulates blood sugar. Mounjaro is also taken once a week, with doses gradually increasing to reduce side effects. Many people report strong appetite suppression and steady weight loss, particularly if they have higher blood glucose levels.
Both medicines can support significant weight loss, but the results may differ depending on individual circumstances. Wegovy typically produces gradual, steady weight loss over months. Mounjaro may offer slightly greater weight loss in some cases, especially for people with type 2 diabetes or insulin resistance. Both medicines are most effective when combined with diet, regular physical activity, and lifestyle changes rather than used alone.
Although both are weekly injections, the dose escalation schedules differ. Wegovy increases doses at set intervals to help the body adjust and minimise side effects. Mounjaro uses a slightly different schedule due to its dual hormonal action, often requiring smaller increments. For both medicines, taking the injection on the same day each week is important to maintain consistent effects.
Both Wegovy and Mounjaro can cause mild side effects such as nausea, diarrhoea, constipation, or headaches. These are generally temporary and tend to improve as the body adjusts. Because Mounjaro works on two hormones, some people may experience slightly stronger digestive effects initially. Any persistent or severe side effects should be discussed with a UK clinician.
The choice between Wegovy and Mounjaro depends on individual needs. Wegovy is suitable for people whose main issue is appetite control and portion management. Mounjaro may be better for those who also need help with blood glucose regulation. In all cases, a clinician in the UK will consider medical history, weight goals, and lifestyle before recommending a treatment.
In conclusion, Wegovy and Mounjaro are not the same. Wegovy focuses on appetite control through GLP-1, while Mounjaro targets both GLP-1 and GIP to reduce hunger and improve glucose management. Both medicines can support long-term weight loss in the UK when combined with healthy lifestyle changes. Understanding these differences allows people to make informed decisions and set realistic expectations in consultation with a healthcare professional.
Wegovy works mainly by reducing appetite via the GLP-1 hormone, helping people eat less naturally. Mounjaro targets both GLP-1 and GIP, reducing hunger and improving how the body handles blood sugar. This dual action can benefit those with type 2 diabetes.
Yes, but both are prescription-only and require a clinician’s assessment. Doctors consider weight, medical history, and other health conditions before prescribing either medicine. They monitor progress and adjust doses as needed.
With Wegovy, early appetite changes appear in the first few weeks, but visible weight loss usually occurs after 2–3 months. Mounjaro can produce similar or slightly faster weight loss in some people, particularly if blood glucose control is also needed.
Wegovy gradually increases doses over several weeks to allow the body to adjust. Mounjaro also increases slowly, but in smaller increments to manage the effects of its dual hormones. Skipping doses can reduce effectiveness for both medicines.
Common side effects include nausea, diarrhoea, constipation, and mild headaches. These are usually temporary, most noticeable during early dose increases, and tend to settle after a few weeks. Mounjaro may cause stronger digestive effects initially because it affects two hormones.
People mainly struggling with appetite and portion control may benefit more from Wegovy. Those who also need better blood sugar management may see better results with Mounjaro. A UK clinician will assess individual goals, health conditions, and lifestyle before recommending either treatment.
Yes, both medicines are most effective when combined with a healthy diet, regular physical activity, and lifestyle changes. They are not intended to replace these habits but to support long-term weight management under a clinician’s guidance.
Yes. Wegovy is generally recommended for people whose main concern is appetite control. Mounjaro may be more suitable for those who also need help managing blood sugar or have type 2 diabetes. A UK clinician will evaluate medical history and individual needs before prescribing.
Mounjaro may be more suitable for people with type 2 diabetes because it helps manage blood sugar in addition to reducing appetite. Wegovy can also be used, but its primary effect is appetite control. A clinician will determine which option is safer based on individual health.
Missing a weekly injection can reduce the medicine’s effectiveness. Both Wegovy and Mounjaro should be taken on the same day each week. If a dose is missed, a UK clinician can provide guidance on when to take the next one safely.
© 2025 Crivva - Hosted by Airy Hosting Managed Website Hosting.
